Quarterly Abicipar Is Not Inferior to Monthly Ranibizumab
Assessing RNFL Plus GCIPL Improves Detection of Glaucoma Progression
SLT May Slow VF Decline Further Than Standard Treatment
Exercise Intensity and Glaucoma
Cilioretinal Arteries and Macular Vasculature in Highly Myopic Eyes
Are Ophthalmology Practices Following COVID Guidance for Patient Visits?
Extended-Interval Faricimab Versus Monthly Ranibizumab
Triaging Glaucoma Appointments Amid the Pandemic
Trends in the U.S. Eye Care Workforce
Slit-Lamp Breath Shields Provide Some Protection From COVID-19
HbA1c Modifies Genetic Susceptibility to Severe DR
Novel Device for Rapid Triage of Glaucoma Patients
Look out for the early signs and symptoms of this rare disease.
Explore TEPEZZA now.
TEPEZZA is a trademark owned by or licensed to Horizon.© 2021 Horizon Therapeutics plc P-TEP-01315 08/21
Public & Patients
Museum of the Eye